Cargando…
Eculizumab therapy on a patient with co‐existent lupus nephritis and C3 mutation‐related atypical haemolytic uremic syndrome: a case report
BACKGROUND: Thrombotic microangiopathy (TMA), a rare but serious complication of systemic lupus erythematosus (SLE), is associated with poor outcomes to conventional immunosuppressive therapy. Recently, eculizumab, a humanised monoclonal antibody that blocks the complement factor 5, has been known t...
Autores principales: | Kim, Mi Jung, Lee, Haekyung, Kim, Yon Hee, Jin, So Young, Kim, Hee-Jin, Oh, Doyeun, Jeon, Jin Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944615/ https://www.ncbi.nlm.nih.gov/pubmed/33691638 http://dx.doi.org/10.1186/s12882-021-02293-2 |
Ejemplares similares
-
Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis,
Responsive to Eculizumab
por: Raufi, Alexander G., et al.
Publicado: (2016) -
Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
por: Kim, Jon Jin, et al.
Publicado: (2012) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
A life-threatening case of pregnancy-related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab
por: Puri, Prianka, et al.
Publicado: (2020) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)